Impulse Biomedical
Impulse Biomedical is a Cape Town-based medical device company developing the ZiBiPen reloadable epinephrine auto-injector for anaphylaxis and the Easy Squeezy asthma inhaler assist sleeve, targeting children, elderly patients, and underserved populations in emerging markets with patented, ISO 13485-certified, pre-commercial products.
- Company typePrivate
- Founded2017
- HeadquartersCape Town, South Africa
- Headcount1–10
- GTM typeB2C
- OfferingHardware or Manufacturing
What Impulse Biomedical does
Impulse Biomedical is a South African medical device developer founded in 2017 by biomedical engineers Giancarlo Beukes and Gokul Nair while completing Master's degrees at the University of Cape Town. The company designs, manufactures, and is commercializing two flagship products: the ZiBiPen, a reloadable epinephrine auto-injector for emergency anaphylaxis treatment featuring a cartridge-based architecture that replaces only the drug cartridge rather than the full device, and the Easy Squeezy, an ergonomic reusable sleeve compatible with standard metered-dose inhalers (Asthavent, Ventolin, Ciclovent) that reduces activation force by approximately 80%. Both products are patented in the US, Europe, and Africa, and the company operates under ISO 13485 certification with a SAHPRA Manufacturer's License in South Africa and CE marking on the Easy Squeezy for European market access.
The business model is hardware sales of proprietary medical devices, with the ZiBiPen architecture generating recurring revenue through replacement cartridge sales and the Easy Squeezy sold as a reusable accessory. The company is explicitly pre-revenue, having secured approximately $1.6 million in disclosed venture funding across rounds led by Launch Africa, Futuregrowth Asset Management, the University Technology Fund, Futuregrowth Development Equity Fund, and ANZA Capital. Distribution is being built through pharmacy channels in South Africa, the Maryland Global Gateway Soft Landing Program and The LaunchPort medtech accelerator in Baltimore for US market entry, and direct partnership/inquiry-based enterprise sales.
Target customer segments include children with asthma (5-12 years), elderly patients with reduced hand strength, anaphylaxis and allergy sufferers requiring emergency epinephrine, and underserved populations in developing markets facing affordability barriers. The company's strategic positioning emphasizes patient-led design, affordability, and accessibility, with quantified claims of 88% cost savings over a 5-year period for ZiBiPen versus traditional auto-injectors, 12x lower injury risk, and 26% improvement in asthma control metrics for Easy Squeezy users. Headcount is reported at 1-10 employees, and the team is led by the two co-founders with support from a General Manager, Product Managers, Engineering staff, Quality Lead, Design Lead, and Regulatory & QA Manager.
Impulse Biomedical firmographics
Firmographics- Name
- Impulse Biomedical
- Legal name
- Impulse Biomedical
- Website
- https://impulsebiomed.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Impulse Biomedical is a Cape Town-based medical device company developing the ZiBiPen reloadable epinephrine auto-injector for anaphylaxis and the Easy Squeezy asthma inhaler assist sleeve, targeting children, elderly patients, and underserved populations in emerging markets with patented, ISO 13485-certified, pre-commercial products.
- Ownership category
- akta.pro rank
Impulse Biomedical industry classification
Industry- Product category
- Medical Devices
- NAICS
- Surgical Appliance and Supplies Manufacturing (339113), Surgical and Medical Instrument Manufacturing (339112), Medical Equipment and Supplies Manufacturing (3391)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Auto-Injectors (Disposable & Reusable) (HLAHAIAB)
- akta.pro secondary industry
- Inhalation & Nebulization Devices (Nebulizers, Spacers, Inhaler Accessories) (HLAHAGAE)
Keywords
Where Impulse Biomedical is headquartered
LocationHeadquarters
- HQ city
- Cape Town
- HQ country
- South Africa
- HQ region
- Africa
Offices2 records
Markets served
Impulse Biomedical business model
Business model- GTM type
- B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure
Revenue model
- Medical Device Sales: Sale of proprietary medical devices including the ZiBiPen reloadable autoinjector and Easy Squeezy asthma assist device. The reloadable design of ZiBiPen creates ongoing revenue through replacement cartridge sales while Easy Squeezy is offered as a reusable device. Company is currently pre-revenue and raising funds to scale manufacturing and secure regulatory approvals.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels6 records
Impulse Biomedical product offering
Product offeringCore offering
Impulse Biomedical designs, develops, and manufactures proprietary medical devices for asthma and allergy management. Its core products are the ZiBiPen, a patented reloadable epinephrine auto-injector for emergency anaphylaxis treatment that reduces cost by replacing only the drug cartridge, and the Easy Squeezy, an ergonomic reusable sleeve that fits over standard metered-dose inhalers to reduce activation force by 80%, enabling independent use by children and elderly patients.
Product overview
Impulse Biomedical is a medical device development company offering two core products: Easy Squeezy (an asthma inhaler accessibility accessory sleeve) and ZiBiPen (a reloadable epinephrine auto-injector). Both devices are designed to improve accessibility and affordability of life-saving medical treatments, particularly for children, elderly, and patients in developing regions. The company operates from South Africa with expansion into the US market via the Maryland Global Gateway program at The LaunchPort in Baltimore.
Differentiator
Problem solved
Functional benefit
Products and services
- Easy Squeezy An ergonomic reusable sleeve that fits over standard metered-dose asthma inhalers (compatible with Asthavent, Ventolin, and Ciclovent brands), reducing activation force by 80% (4x easier). Includes a built-in dose counter and child-friendly decorative characters to reduce stigma. Clinically proven to improve asthma control by 26% and lower treatment age from 12 to 5 years. Designed for children, elderly patients, and anyone with limited finger strength.
- ZiBiPen A reloadable adrenaline (epinephrine) auto-injector for emergency treatment of life-threatening anaphylaxis. Features a user-friendly design with reloadable cartridge (replacing only the drug cartridge rather than the entire device), safety cap, clear medication window, adjustable needle length, and dosage indicator. Clinically validated with pharmacokinetic trials confirming drug delivery effectiveness comparable to leading competitors. Offers 88% cost savings over a 5-year period versus traditional auto-injectors and 12x lower injury risk.
Quantifiable outcome
- 80% reduction in activation force for asthma inhalers (Easy Squeezy)
- +5 more outcomes
Companies that use Impulse Biomedical
Customer profileSegments4 records
Ideal customer profiles3 records
Impulse Biomedical technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Impulse Biomedical partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and minor.
- Maryland Department of CommercecoreMaryland Department of Commerce administers the Global Gateway Soft Landing Program that officially welcomed Impulse Biomedical. The program provides international companies support and resources to establish US presence, including access to facilities, capital, and partner advisors with industry knowledge. The state announced Impulse Biomed's medtech sector win at SelectUSA Investment Summit.
- The LaunchPortcoreThe LaunchPort is a Medtech manufacturing accelerator in Baltimore, MD where Impulse officially took up residence as part of its global expansion. The facility offers regulatory expertise, manufacturing infrastructure, and commercial partnership opportunities essential for US market entry. Impulse will explore manufacturing and sterilization partnerships through this accelerator.
- University of Cape TowncoreBoth ZiBiPen and Easy Squeezy were developed while founders Gokul Nair and Giancarlo Beukes completed Master's degrees in Biomedical Engineering at UCT. The Easy Squeezy was developed in collaboration with Dr Michael Levin, Head of Division of Asthma and Allergy at Red Cross Children's Hospital. Company maintains ongoing partnerships with UCT Med-Tech and University Tech Fund.
- Allergy Foundation of South AfricaminorPartner organization supporting allergy awareness and treatment access in South Africa, listed among collaborative successes on company website.
- UCT Med-TechminorUniversity of Cape Town medical technology initiative supporting biomedical innovation and commercialization, listed among collaborative successes.
Scale indicators9 records
Recent moves8 records
Expansion highlights5 records
Impulse Biomedical competitors and assessment
Company assessmentBroad incumbents
- AstraZeneca: AstraZeneca markets major respiratory brands (Symbicort, Breztri) and is investing heavily in respiratory biologics. Comparable as a broad respiratory incumbent whose inhaler portfolio is compatible with the Easy Squeezy device.
- Teva Pharmaceutical Industries: Teva markets a generic EpiPen competitor as well as a broad respiratory portfolio (including ProAir inhalers compatible with Easy Squeezy). Operates in both of Impulse's core categories at scale with established distribution and regulatory infrastructure.
- GlaxoSmithKline (GSK): GSK is a global leader in respiratory medicine (Ventolin, Advair, Trelegy) and would be a key inhaler manufacturer whose products are compatible with the Easy Squeezy. As a broad incumbent, GSK dwarfs Impulse in R&D and commercial reach, but its inhaler franchise is the natural target market for the Easy Squeezy sleeve.
Direct peers
- Viatris (EpiPen): Viatris markets the EpiPen, the dominant single-use epinephrine auto-injector that Impulse's ZiBiPen directly competes against. Comparable on indication (anaphylaxis), patient population, and delivery modality, though Viatris operates at vastly greater scale and with a single-use (non-reloadable) architecture.
- Kaleo (AUVI-Q): Kaleo manufactures AUVI-Q, a competing epinephrine auto-injector with voice-guided instructions. Direct competitor to ZiBiPen in the US anaphylaxis market, with comparable device form factor but differentiated by features (voice guidance vs. reloadable cartridge).
- MannKind Corporation: MannKind develops inhaled drug delivery systems (Afrezza inhaler) and has a deep focus on innovative, patient-friendly inhaler technology. Comparable as a smaller specialty drug delivery company focused on inhalers, with similar disruptive positioning against large incumbents.
- Amphastar Pharmaceuticals: Amphastar manufactures generic epinephrine auto-injectors (Symjepi) and competes with both EpiPen and ZiBiPen in the anaphylaxis space. Direct competitor on product category and indication, with focus on affordability similar to Impulse's positioning.
Emerging players
- Insulet Corporation: Insulet's Omnipod is a reloadable, wearable drug delivery device (for insulin) that shares Impulse's architectural philosophy of reloadable cartridges replacing single-use devices. Comparable on the reloadable consumable model that anchors Impulse's value proposition.
- ResMed (Propeller Health): ResMed's Propeller Health business offers digital inhaler sensors and companion software to improve asthma adherence and technique—addressing overlapping problems (poor inhaler technique in children and adults) as Impulse's Easy Squeezy, but via digital rather than mechanical intervention.
Others
- Halozyme Therapeutics: Halozyme licenses its ENHANZE drug delivery platform to pharma partners for subcutaneous delivery of biologics. Comparable as an enabling drug delivery technology company in the broader medical device space, though focused on biologic formulations rather than emergency rescue injectors.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Impulse Biomedical social profiles
Digital presenceImpulse Biomedical compliance and trust
Trust signalCompliance4 records
Impulse Biomedical financial estimates
Financial estimateRevenue estimate
Valuation estimate
Impulse Biomedical leadership team
Management profileNumber of profiles
Profiles12 records
Impulse Biomedical funding detail
Funding detailFunding overview
Funding rounds3 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Impulse Biomedical M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Impulse Biomedical
What does Impulse Biomedical do?
Impulse Biomedical designs, develops, and manufactures proprietary medical devices for asthma and allergy management. Its core products are the ZiBiPen, a patented reloadable epinephrine auto-injector for emergency anaphylaxis treatment that reduces cost by replacing only the drug cartridge, and the Easy Squeezy, an ergonomic reusable sleeve that fits over standard metered-dose inhalers to reduce activation force by 80%, enabling independent use by children and elderly patients.
Is Impulse Biomedical a public or private company?
Impulse Biomedical is a private company. It is classified as venture growth investor backed and is currently operating.
When was Impulse Biomedical founded?
Impulse Biomedical was founded in 2017. It employs 1 to 10 people.
Where is Impulse Biomedical based?
Impulse Biomedical is headquartered in Cape Town, South Africa, in the Africa region.
How does Impulse Biomedical make money?
One revenue line is on record: medical Device Sales.
Who are Impulse Biomedical's main competitors?
Broad incumbents on record are AstraZeneca, Teva Pharmaceutical Industries and GlaxoSmithKline (GSK). Direct peers are Viatris (EpiPen), Kaleo (AUVI-Q), MannKind Corporation and Amphastar Pharmaceuticals. Emerging players are Insulet Corporation and ResMed (Propeller Health). Halozyme Therapeutics is listed as an others.
Does Impulse Biomedical have an API?
No public API is recorded for Impulse Biomedical.
What industry is Impulse Biomedical in?
Impulse Biomedical's product category is Medical Devices. Its primary akta.pro industry code is HLAHAIAB, Auto-Injectors (Disposable & Reusable), with a secondary code of HLAHAGAE, Inhalation & Nebulization Devices (Nebulizers, Spacers, Inhaler Accessories). Its NAICS code is 339113 and its SIC code is 3841.